Alector (ALEC) Expected to Announce Quarterly Earnings on Wednesday

Alector (NASDAQ:ALEC) is anticipated to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Alector to post earnings of ($0.40) per share and revenue of $3.4870 million for the quarter. Alector has set its FY 2025 guidance at EPS.Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:00 PM ET.

Alector (NASDAQ:ALEC) last issued its earnings results on Thursday, August 7th. The company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.15. The firm had revenue of $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector had a negative net margin of 142.10% and a negative return on equity of 112.06%. On average, analysts expect Alector to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alector Stock Performance

Shares of ALEC stock opened at $1.50 on Wednesday. The company has a current ratio of 3.78, a quick ratio of 3.78 and a debt-to-equity ratio of 0.13. The firm has a fifty day moving average price of $2.75 and a 200 day moving average price of $1.90. The company has a market cap of $151.82 million, a P/E ratio of -1.29 and a beta of 0.99. Alector has a 12 month low of $0.87 and a 12 month high of $6.14.

Insiders Place Their Bets

In related news, Director Paula Hammond sold 14,000 shares of the business’s stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $2.36, for a total value of $33,040.00. Following the completion of the sale, the director directly owned 74,909 shares of the company’s stock, valued at $176,785.24. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alector

Institutional investors and hedge funds have recently made changes to their positions in the business. Prudential Financial Inc. purchased a new stake in shares of Alector in the second quarter valued at about $30,000. XTX Topco Ltd raised its holdings in shares of Alector by 125.2% in the second quarter. XTX Topco Ltd now owns 73,338 shares of the company’s stock valued at $103,000 after buying an additional 40,767 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Alector by 87.9% in the second quarter. Russell Investments Group Ltd. now owns 100,366 shares of the company’s stock valued at $144,000 after buying an additional 46,945 shares during the last quarter. Strs Ohio purchased a new stake in shares of Alector in the first quarter valued at about $126,000. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Alector in the second quarter valued at about $161,000. 85.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Mizuho set a $1.50 target price on shares of Alector and gave the stock a “neutral” rating in a research note on Wednesday, October 22nd. HC Wainwright reduced their price target on shares of Alector from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, October 22nd. Cowen cut shares of Alector to a “hold” rating in a research report on Wednesday, October 22nd. Wall Street Zen cut shares of Alector from a “hold” rating to a “sell” rating in a research report on Friday, September 26th. Finally, Cantor Fitzgerald cut shares of Alector from an “overweight” rating to a “neutral” rating in a research report on Wednesday, October 22nd. One equities research analyst has rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $3.00.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.